Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Conditions

• Colonic Diseases
• Colorectal Neoplasms
• Digestive System Diseases
• Digestive System Neoplasms
• Gastrointestinal Diseases
• Gastrointestinal Neoplasms
• Intestinal Diseases
• Intestinal Neoplasms
• Neoplasms by Site
• Rectal Diseases

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• PF-08634404 — DRUG
  Solution for infusion
• Bevacizumab — BIOLOGICAL
  Injection for intravenous use
• Chemotherapy — DRUG
  Injection for intravenous use

Study Details

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have colorectal cancer that has spread to other parts of your body. * Be in good enough health to receive study treatment. * Should not be pregnant before starting treatment. Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects. The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment. * The study is expected to last approximately 33 months for each participant. * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status and any new treatments.

Key Dates

Start date

Dec 11, 2025

Status verified

Jun 2026

Primary completion

Mar 29, 2030

Completion

Aug 1, 2031

Study Design

Enrollment

800 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: PF-08634404 + Chemotherapy
  Participants will receive PF-08634404 intravenously (IV) in combination with Chemotherapy.
• Active Comparator: Bevacizumab + Chemotherapy
  Participants will receive bevacizumab IV in combination with Chemotherapy.

Primary Outcome Measure

Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) [ Time Frame: Approximately 4 years ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (150)

Find similar trials in Chandler, AZ

Related Studies

• The Clinical Impact and Outcomes of Interventional Endoscopy Procedures
  Enrolling By Invitation · University of California, Irvine · Orange, California
• Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions
  Recruiting · California Pacific Medical Center Research Institute · San Francisco, California
• Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
  PHASE3 · Recruiting · Surgimab · Duarte, California
• HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Birmingham, Alabama